Trial Profile
A Phase 1 Dose-Escalation Study To Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed By an Open-Label Evaluation of LX214 Ophthalmic Solution in Patients With Keratoconjunctivitis Sicca
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2014
Price :
$35
*
At a glance
- Drugs Voclosporin (Primary)
- Indications Dry eyes; Keratoconjunctivitis sicca
- Focus First in man; Therapeutic Use
- Sponsors Lux Biosciences
- 12 May 2014 New trial record